Perioperative Hemodynamic Control - Adrenergic Pharmacology (Table 20.2)

Perioperative Hemodynamic Control - Adrenergic Pharmacology (Table 20.2) is a topic covered in the Clinical Anesthesia Procedures.

To view the entire topic, please or .

Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drug, procedures and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and MEDLINE Journals. Explore these free sample topics:

-- The first section of this topic is shown below --

α-Agonists

α-Agonists

  1. Phenylephrine is a direct-acting α1-agonist at typical clinical doses (40 to 200 mcg/min infusion), with some β-receptor activity at higher doses or with concurrent α-blockade. Phenylephrine causes both arterial and venous vasoconstriction. This dual action increases venous return and mean arterial blood pressure, frequently resulting in reflex bradycardia. Phenylephrine maintains cardiac output in patients with normal myocardial function but may decrease cardiac performance in the presence of myocardial ischemia. Phenylephrine has a short duration of action, which makes it easily titratable.
  2. Clonidine is a centrally acting antihypertensive with relative selectivity for α2-adrenoreceptors. Its actions include reducing sympathetic tone, increasing parasympathetic activity, reducing anesthetic and analgesic requirements, causing sedation, and decreasing salivation. It can be administered intravenously, intramuscularly, orally, transcutaneously, and into the intrathecal and epidural spaces.
  3. Dexmedetomidine is a selective α2-adrenoreceptor agonist currently approved for the short-term (<24 hours) intravenous sedation of mechanically ventilated patients in an intensive care setting. Its action on presynaptic receptors inhibits the release of norepinephrine, and its activation of postsynaptic α2-receptors in the CNS inhibits sympathetic activity. These effects decrease blood pressure and heart rate. Dexmedetomidine offers potential advantages over other sedatives, including lack of respiratory depression, lower rates of associated delirium, and a decreased incidence of hypotension.

-- To view the remaining sections of this topic, please or --

α-Agonists

α-Agonists

  1. Phenylephrine is a direct-acting α1-agonist at typical clinical doses (40 to 200 mcg/min infusion), with some β-receptor activity at higher doses or with concurrent α-blockade. Phenylephrine causes both arterial and venous vasoconstriction. This dual action increases venous return and mean arterial blood pressure, frequently resulting in reflex bradycardia. Phenylephrine maintains cardiac output in patients with normal myocardial function but may decrease cardiac performance in the presence of myocardial ischemia. Phenylephrine has a short duration of action, which makes it easily titratable.
  2. Clonidine is a centrally acting antihypertensive with relative selectivity for α2-adrenoreceptors. Its actions include reducing sympathetic tone, increasing parasympathetic activity, reducing anesthetic and analgesic requirements, causing sedation, and decreasing salivation. It can be administered intravenously, intramuscularly, orally, transcutaneously, and into the intrathecal and epidural spaces.
  3. Dexmedetomidine is a selective α2-adrenoreceptor agonist currently approved for the short-term (<24 hours) intravenous sedation of mechanically ventilated patients in an intensive care setting. Its action on presynaptic receptors inhibits the release of norepinephrine, and its activation of postsynaptic α2-receptors in the CNS inhibits sympathetic activity. These effects decrease blood pressure and heart rate. Dexmedetomidine offers potential advantages over other sedatives, including lack of respiratory depression, lower rates of associated delirium, and a decreased incidence of hypotension.

There's more to see -- the rest of this entry is available only to subscribers.